See more : EnerNorth Industries Inc. (ENYNF) Income Statement Analysis – Financial Results
Complete financial analysis of MEI Pharma, Inc. (0JW9.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MEI Pharma, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Arsenal Digital Holdings, Inc. (GGRN) Income Statement Analysis – Financial Results
- Allied Group Limited (ALEDY) Income Statement Analysis – Financial Results
- YGM Trading Limited (0375.HK) Income Statement Analysis – Financial Results
- Ball Corporation (0HL5.L) Income Statement Analysis – Financial Results
- Stingray Group Inc. (RAY-A.TO) Income Statement Analysis – Financial Results
MEI Pharma, Inc. (0JW9.L)
About MEI Pharma, Inc.
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.30M | 48.82M | 40.70M | 25.54M | 28.91M | 4.92M | 1.62M | 23.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 84.00K | 228.00K | 674.00K | 645.00K | -120.00K | 308.00K | 193.00K | 145.00K | 7.00K |
| Cost of Revenue | 383.00K | 1.82M | 1.24M | 1.41M | 2.67M | 4.26M | 3.38M | 5.00M | 58.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 0.00 |
| Gross Profit | 64.91M | 47.00M | 39.46M | 24.13M | 26.24M | 652.00K | -1.76M | 18.25M | -58.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 84.00K | 228.00K | 674.00K | 645.00K | -120.00K | 308.00K | 193.00K | -355.00K | 7.00K |
| Gross Profit Ratio | 99.41% | 96.28% | 96.97% | 94.49% | 90.76% | 13.27% | -108.57% | 78.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -244.83% | 100.00% |
| Research & Development | 16.56M | 52.45M | 85.64M | 69.40M | 34.07M | 32.30M | 17.04M | 7.24M | 13.40M | 23.82M | 19.33M | 6.08M | 4.92M | 2.12M | 4.03M | 7.78M | 9.33M | 5.76M | 3.43M | 2.28M | 2.38M | 2.02M | 0.00 |
| General & Administrative | 23.30M | 33.13M | 30.54M | 24.41M | 16.72M | 14.60M | 9.79M | 8.63M | 5.67M | 7.18M | 6.45M | 5.14M | 3.48M | 4.34M | 0.00 | 0.00 | 0.00 | 488.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.30M | 33.13M | 30.54M | 24.41M | 16.72M | 14.60M | 9.79M | 8.63M | 5.67M | 7.18M | 6.45M | 5.14M | 3.48M | 4.34M | 3.95M | 3.63M | 3.76M | 8.70M | 4.40M | 4.45M | 6.35M | 654.00K | 0.00 |
| Other Expenses | 10.90M | -22.00K | -6.00K | 486.00K | 0.00 | 0.00 | 15.42M | 4.87M | 1.93M | 1.77M | 1.45M | 0.00 | 3.48M | 4.34M | 3.95M | 3.63M | 4.43M | 8.70M | 3.96M | 4.45M | 6.35M | 654.00K | 129.00K |
| Operating Expenses | 50.76M | 85.58M | 116.18M | 93.81M | 50.78M | 46.90M | 26.83M | 15.87M | 21.00M | 32.77M | 27.23M | 11.22M | 8.39M | 6.45M | 7.98M | 11.41M | 13.76M | 14.46M | 7.39M | 6.73M | 8.73M | 2.68M | 129.00K |
| Cost & Expenses | 50.76M | 85.58M | 116.18M | 95.22M | 53.45M | 51.16M | 30.21M | 20.87M | 21.00M | 32.77M | 27.23M | 11.22M | 8.39M | 6.45M | 7.98M | 11.41M | 13.76M | 14.46M | 7.39M | 6.73M | 8.73M | 3.18M | 129.00K |
| Interest Income | 3.28M | 3.35M | 284.00K | 510.00K | 1.40M | 1.80M | 591.00K | 287.00K | 143.00K | 78.00K | 81.00K | 37.00K | 39.00K | 130.00K | 84.00K | 228.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 284.00K | 0.00 | 0.00 | 0.00 | 2.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 383.00K | 1.82M | 1.24M | 285.00K | 109.00K | 80.00K | 53.00K | 85.00K | 58.00K | 64.00K | 50.00K | 45.00K | 13.00K | 13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 26.38M | -36.76M | -75.16M | -60.14M | -25.59M | -46.17M | -28.53M | 2.47M | -20.95M | -32.71M | -27.18M | -11.18M | -7.10M | -6.77M | -7.90M | -11.18M | -13.08M | -13.82M | -7.39M | -6.42M | -8.54M | -3.03M | -122.00K |
| EBITDA Ratio | 40.40% | -77.80% | -235.67% | -342.75% | -5.40% | -1,501.46% | -1,160.79% | 10.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,398.81% | -4,903.07% | -1,940.80% | -2,142.48% | 6,154.17% | -2,084.74% | -4,423.83% | -2,091.72% | -1,742.86% |
| Operating Income | 14.54M | -36.76M | -75.48M | -69.69M | -24.54M | -46.25M | -28.59M | 2.38M | -21.00M | -32.77M | -27.23M | -11.22M | -8.39M | -6.45M | -7.90M | -11.18M | -13.08M | -13.82M | -7.39M | -6.42M | -8.54M | -3.03M | -122.00K |
| Operating Income Ratio | 22.27% | -75.31% | -185.48% | -272.90% | -84.88% | -940.90% | -1,762.39% | 10.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,398.81% | -4,903.07% | -1,940.80% | -2,142.48% | 6,154.17% | -2,084.74% | -4,423.83% | -2,091.72% | -1,742.86% |
| Total Other Income/Expenses | 3.24M | 4.93M | 21.03M | 19.12M | -21.48M | 29.43M | -11.48M | 287.00K | 143.00K | 78.00K | 81.00K | 37.00K | 872.00K | -329.00K | 0.00 | 0.00 | 674.00K | 0.00 | 444.00K | 284.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 17.78M | -31.84M | -54.45M | -50.57M | -46.02M | -16.82M | -40.07M | 2.67M | -20.86M | -32.69M | -27.15M | -11.19M | -7.52M | -6.78M | -7.90M | -11.18M | -12.41M | -13.82M | -7.39M | -6.42M | -8.54M | -3.03M | -122.00K |
| Income Before Tax Ratio | 27.23% | -65.22% | -133.80% | -198.03% | -159.15% | -342.18% | -2,470.22% | 11.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,398.81% | -4,903.07% | -1,840.80% | -2,142.48% | 6,154.17% | -2,084.74% | -4,423.83% | -2,091.72% | -1,742.86% |
| Income Tax Expense | 0.00 | -4.95M | 284.00K | 8.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 3.00K | 1.00K | 1.00K | 0.00 | 0.00 | 0.00 | 1.00K |
| Net Income | 17.78M | -31.84M | -54.45M | -41.31M | -47.17M | -16.82M | -40.07M | 2.67M | -20.86M | -32.69M | -27.15M | -11.19M | -7.52M | -6.78M | -7.90M | -11.18M | -12.41M | -13.82M | -7.39M | -6.42M | -8.54M | -3.03M | -123.00K |
| Net Income Ratio | 27.23% | -65.22% | -134.50% | -198.06% | -159.15% | -342.20% | -2,470.28% | 11.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,400.00% | -4,903.51% | -1,841.25% | -2,142.64% | 6,155.00% | -2,084.74% | -4,423.83% | -2,091.72% | -1,757.14% |
| EPS | 2.67 | -4.78 | -8.75 | -7.40 | -10.40 | -4.73 | -19.34 | 1.40 | -12.20 | -23.20 | -27.06 | -22.02 | -66.94 | -106.46 | -128.98 | -183.60 | -218.03 | -262.42 | -155.67 | -135.33 | -186.44 | -69.96 | -2.97 |
| EPS Diluted | 2.67 | -4.78 | -9.99 | -12.00 | -10.40 | -4.65 | -19.34 | 1.45 | -12.13 | -23.18 | -27.06 | -22.02 | -66.94 | -106.46 | -128.98 | -183.60 | -218.03 | -262.42 | -155.67 | -135.33 | -186.44 | -69.96 | -2.97 |
| Weighted Avg Shares Out | 6.66M | 6.66M | 6.22M | 5.63M | 4.55M | 3.56M | 2.07M | 1.85M | 1.71M | 1.41M | 1.00M | 508.04K | 112.39K | 63.70K | 61.22K | 60.89K | 56.92K | 52.66K | 47.45K | 47.45K | 45.80K | 43.35K | 41.47K |
| Weighted Avg Shares Out (Dil) | 6.66M | 6.66M | 6.26M | 5.72M | 4.55M | 3.62M | 2.07M | 1.91M | 1.72M | 1.41M | 1.00M | 508.04K | 112.39K | 63.70K | 61.22K | 60.89K | 56.92K | 52.66K | 47.45K | 47.45K | 45.80K | 43.35K | 41.47K |
Source: https://incomestatements.info
Category: Stock Reports